C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $295.66M
• Dividend Yield: N/A
• Average Volume (3M): 1.91M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: -10.57%
• EPS Growth: 1.98%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 97,578,180
• 10 Day Avg. Volume: 3,943,023
• 30 Day Avg. Volume: 1,905,031
• PEG Ratio: 0.09
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 4.40
• P/FCF Ratio: -1.59
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 5.86
• Enterprise Value/Gross Profit: 6.17
• Enterprise Value/Ebitda: -1.95
• 1Y Price Target: $12.75
• Price Target Upside: 319.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.09
• Revenue Forecast (FY): $21.62M

• Rating: 51 Neutral
• Price Target: $3.00 ▼(-1.32% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily held back by weak financial performance (persistent losses and significant cash burn), only partially offset by a comparatively stronger balance sheet. Technicals are supportive with strong momentum, but overbought signals elevate near-term risk. Valuation contributes modestly negative impact because losses make P/E less informative and there is no dividend support.

Positive Factors

Cash runway through end of 2028

A multi-year cash runway through end-2028 materially reduces near-term financing pressure and allows the company to execute planned Phase 1/2/3 trials and partnership activities. This funding horizon supports delivery of clinical readouts that are critical to de-risking the business model over the medium term.

Strategic collaborations with major pharma

Ongoing collaborations with established pharmas provide development expertise, potential co-funding, and commercial pathways. These partnerships can accelerate development, share regulatory and development risk, and enhance the probability of later-stage success and market access compared with going solo.

Proprietary TORPEDO platform and encouraging Phase 1 data

A platform-focused approach (TORPEDO) plus Phase 1 response signals for cemsidomide indicate differentiated scientific capability and potential first-mover or best-in-class positioning in targeted protein degradation for oncology. If clinical efficacy and safety hold, platform and lead-program success can deliver durable competitive advantage.

Negative Factors

Material negative operating and free cash flow

Large and persistent negative operating and free cash flows indicate ongoing cash burn that will require external financing absent rapid progress to revenue or partnership cash. Over the medium term this raises dilution risk, limits optionality, and forces management to prioritize financing and milestone delivery over long-term value creation.

Revenue collapse and lack of product sales

A drop to zero reported revenue highlights a structural gap: the company remains pre-commercial and cannot rely on product sales to fund operations. Sustained absence of revenue means advances hinge entirely on trial outcomes and partnerships, making durable profitability and self-funded growth uncertain.

High binary clinical and regulatory risk

As a clinical-stage biotech without approved products, long-term value is tightly linked to successful trials and regulatory approvals. Trial setbacks or delays would materially impair revenue prospects and extend funding needs, creating a binary outcome profile that elevates execution and financing risk over the coming years.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that seek to leverage its proprietary protein degradation technology. The company may receive upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on sales of products developed through these collaborations. Additionally, C4 Therapeutics may engage in grant funding or government contracts to support research and development efforts. The success of its revenue model is heavily reliant on the advancement of its drug candidates through clinical trials and their eventual commercialization in partnership with established pharmaceutical companies.

C4 Therapeutics Financial Statement Overview

Summary

Overall financials are weak: the company is deeply unprofitable with persistent operating/net losses and ongoing negative operating and free cash flow (material cash burn). The balance sheet is a relative offset with moderate leverage and meaningful equity, but sustainability remains a key risk without a return to durable revenue.

Income Statement

The company remains deeply unprofitable, with large operating and net losses each year (2020–2025). Revenue has been volatile and has deteriorated sharply, falling to $0 in 2025 (annual report), implying a severe disruption in recurring revenue generation versus prior years (e.g., ~$35.6M in 2024). Gross profit has also been inconsistent, including a notably weak 2020 result and a complete absence of revenue in 2025, while operating losses have not meaningfully improved—highlighting a cost structure that is not yet scaling with revenue.

Balance Sheet

The balance sheet is a relative strength: leverage is moderate with debt-to-equity around ~0.23 in 2025 (annual report) and generally in the ~0.08–0.30 range historically. Equity remains sizable ($256.6M in 2025) versus total debt ($60.0M), which provides financial flexibility. However, persistent losses translate into consistently negative returns on equity, and equity has fluctuated over time, suggesting ongoing cash burn and potential future financing needs if profitability does not improve.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow negative every year shown (e.g., 2025 operating cash flow of -$98.7M and free cash flow of -$99.3M). While free cash flow-to-net income is around ~1.0 in most periods, this is largely because both figures are negative (cash burn tracking accounting losses rather than offsetting them). Free cash flow growth is also inconsistent year-to-year, and the ongoing magnitude of cash burn elevates funding and dilution risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	35.95M	35.58M	20.76M	31.10M	45.78M
Gross Profit	27.97M	35.58M	13.02M	31.10M	45.78M
EBITDA	-102.91M	-103.37M	-122.10M	-124.28M	-80.25M
Net Income	-104.99M	-105.32M	-132.49M	-128.18M	-83.89M
Balance Sheet
Total Assets	359.07M	349.60M	376.45M	430.84M	506.76M
Cash, Cash Equivalents and Short-Term Investments	248.54M	244.90M	253.68M	276.15M	309.28M
Total Debt	59.98M	65.76M	70.98M	87.15M	42.88M
Total Liabilities	102.49M	133.62M	130.34M	141.61M	117.16M
Stockholders Equity	256.59M	215.99M	246.11M	289.23M	389.61M
Cash Flow
Free Cash Flow	-99.30M	-65.34M	-108.55M	-111.44M	-88.24M
Operating Cash Flow	-98.69M	-65.16M	-106.84M	-105.94M	-86.97M
Investing Cash Flow	-8.60M	-51.27M	158.35M	58.42M	-189.34M
Financing Cash Flow	126.40M	45.34M	45.49M	1.15M	171.40M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 3.04 is above the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.19, and above the 200-day MA of 2.22, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 69.43 is Neutral, neither overbought nor oversold. The STOCH value of 83.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLS	56 Neutral	$752.10M	-6.42	-84.33%	―	―	59.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CCCC	51 Neutral	$295.66M	-1.51	-44.44%	―	-10.57%	1.98%
MCRB	50 Neutral	$86.12M	5.14	15.95%	―	448.44%	―
ELDN	44 Neutral	$196.72M	-2.86	-95.49%	―	―	72.35%
TVGN	41 Neutral	$1.57B	-6.72	―	―	―	-234.46%

C4 Therapeutics Corporate Events

C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy

On January 14, 2026, C4 Therapeutics outlined a multi-year strategy centered on advancing its lead IKZF1/3 degrader cemsidomide toward potential best-in-class status in multiple myeloma, alongside a refocused discovery effort on novel targets in validated inflammatory and neuro-inflammatory pathways. The company plans to start the Phase 2 MOMENTUM trial of cemsidomide plus dexamethasone in the first quarter of 2026 using a 100 µg dose, initiate a Phase 1b study with elranatamab in the second quarter of 2026, and work toward pivotal data readouts and a potential U.S. new drug application in fourth-line or later multiple myeloma by year-end 2028, supported by Phase 1 data from 2025 showing overall response rates of 40% and 53% at the two highest dose levels. C4T also detailed a goal to begin a Phase 3 trial of cemsidomide in combination with a BCMA bispecific antibody by early 2028, use data from its CFT8919 program in China to guide ex-China development in 2026, and file up to three investigational new drug applications from its internal discovery pipeline by 2028. The company reported that its cash runway extends to the end of 2028, providing funding through several clinical and partnership milestones, including advancement of collaborations with Merck KGaA, Roche and Biogen, positioning C4T to strengthen its presence in targeted protein degradation and potentially enhance value for patients and investors if the planned trials and discovery initiatives succeed.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.